Our mission: To develop safer and more effective immunotherapies through innovations in drug delivery.
Avidea Technologies is a leader in the development of polymer-based drug delivery systems for immunotherapeutic applications.
Our technology and team are building on more than two decades of pioneering work by our world-class scientific founders and advisors from the National Institutes of Health, the University of Oxford and the Institute for Macromolecular Chemistry. Our founders, advisors and collaborators are experts in the fields of immunology, oncology, vaccines and drug delivery.
We apply the interdisciplinary expertise of our team to overcome key challenges in drug delivery and advance promising immunotherapies to patients in need.
Geoffrey M. Lynn, Ph.D.
Chief Executive Officer and co-founder
Dr. Geoffrey Lynn has leveraged his background in synthetic chemistry and cellular immunology to lead a 10+ year effort to develop immunotherapies enabled by polymer-based drug delivery systems. Dr. Lynn has authored several seminal publications on drug delivery systems and holds multiple patents covering immunotherapy platform technologies. Dr. Lynn co-founded Avidea following a post-doctoral fellowship with Dr. Robert Seder at the Vaccine Research Center, National Institutes of Health. Dr. Lynn attended medical school at Johns Hopkins University and obtained a Ph.D. in Biomedical Engineering from the University of Oxford.
Andrew S. Ishizuka, Ph.D.
Chief Scientific Officer and co-founder
Dr. Andrew Ishizuka is an expert in T cell immunology and translational research. Dr. Ishizuka has authored numerous publications describing novel translational research studies related to vaccine-induced T cell responses from mice, non-human primates, and humans. Dr. Ishizuka is a named inventor on multiple patents covering immunotherapy platform technologies. Prior to co-founding Avidea, Dr. Ishizuka was a post-doctoral fellow with Dr. Robert Seder at the Vaccine Research Center, National Institutes of Health. Dr. Ishizuka attended medical school at Duke University and obtained a Ph.D. in Clinical Medicine from the University of Oxford.
Richard Laga, Ph.D.
Co-founder and Principal Investigator at IMC
Dr. Richard Laga is an expert in polymer chemistry specializing in polymer-drug conjugates (i.e. small molecule drugs, proteins and genetic material), particularly immunotherapies, for the treatment of cancer and infectious diseases. Dr. Laga is the Deputy Head of the Bioactive Polymers Department and Head of the Laboratory of Polymer Nanotherapeutics at the Institute of Macromolecular Chemistry (IMC) of the Czech Academy of Sciences. Dr. Laga was a post-doctoral fellow with Prof. Leonard Seymour in the Department of Oncology at the University of Oxford and completed his Ph.D. in the field of Macromolecular Chemistry in the Department of Biomedical Polymers at IMC under the supervision of Prof. Karel Ulbrich.
Michele Wales, J.D., Ph.D.
Head of Intellectual Property
Michele Wales, J.D., Ph.D., brings over 20 years of experience in intellectual property strategy and patent prosecution to Avidea. An inventor on numerous patents, Dr. Wales is currently Principal and Founder of InHouse Patent Counsel, LLC, and was formerly the head of Litigation and Intellectual Property at Human Genome Sciences. Under her direction, HGS’ IP portfolio was repeatedly recognized by the Wall Street Journal as one of the “Top 10 Biotech Portfolios,” covering over 10,000 human genes, proteins and antibodies. She also successfully managed the team that established the Utility Standard for gene-based patents at the United Kingdom’s Supreme Court and European Patent Office. The International Law Office nominated her team in 2012 as “In-House Litigation Team of the Year.” Dr. Wales received her J.D. from George Washington National Law Center and her Ph.D. in Human Genetics and Molecular Biology from Johns Hopkins University.
Prof. Nina Bhardwaj, M.D., Ph.D.
Prof. Nina Bhardwaj is Director of Immunotherapy at the Icahn School of Medicine at Mount Sinai (ISMMS) and holds the Ward Coleman Chair in Cancer Research. As a leading medical oncologist, she has made seminal contributions to understanding and implementing immunotherapies, including authoring over 200 peer-reviewed publications on the subject, and has actively led several Investigator-Initiated clinical studies evaluating Toll Like Receptor (TLR) agonist- and dendritic cell-based vaccines for the treatment of both cancer and certain infectious diseases. Prof. Bhardwaj is currently leading 3 clinical studies evaluating neoantigen vaccines; is an editor for several journals; and serves on various industry and academic advisory councils. In recognition for Prof. Bhardwaj’s significant contributions to advancing the fields of immunology and oncology, she received the Doris Duke Distinguished Scientist Award and was named one of the Scientific American’s Top 50 Researchers.